Thoracotomy and intercostal minimally invasive approaches can precipitate post-thoracotomy pain syndrome via intercostal ...
The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by 3 months to March 3, 2027, for the new drug ...
Burnout remains a significant concern among oncologists, with approximately 60% of oncologists reporting burnout, according ...
Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice ...
The FDA has granted final approval to a laurylsulfate salt formulation of cabozantinib (Omcazio), converting the product’s ...
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed ...
Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting ...
Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials ...
Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.
Early results from the phase 2 RESTORE-PV trial suggest that the investigational monoclonal antibody DISC-3405 has the ...
Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results